new version V2017

Pembrolizumab immune checkpoint inhibition
Description Results

MK-3475 - Keytruda - lambrolizumab      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

gastric or gastro-oesophageal junction cancer (advanced)

KEYNOTE-059pembrolizumabnil - NCT02335411
Keynote 061, 2018pembrolizumabpaclitaxel2L Risk of bias Negative NCT02370498

Head and neck cancer

KEYNOTE-040pembrolizumabstandard treatment2L Risk of bias SuggestingNCT02252042
KEYNOTE-048 ongoing pembrolizumabCetuximab + Platinum + 5FU1L - NCT02358031
Keynote 147 ongoing pembrolizumab +/- acalabrutinibstandard treatment>2L - NCT02454179

lung cancer (metastatic)

Keynote 010 2mg, 2015pembrolizumab 2mgdocetaxel2L, PD-L1 positive Risk of bias SuggestingNCT01905657
Keynote 010 10mg, 2015pembrolizumab 10mgdocetaxel2L, PD-L1 positive Risk of bias SuggestingNCT01905657
Keynote 024, 2015pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02142738
KEYNOTE-021 phase 2, 2016pembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous Exploratory SuggestingNCT02039674
Keynote 042 (>=1%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02220894
Keynote 189, 2018pembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous Low risk of bias ConclusiveNCT02578680
Keynote 407, 2018pembrolizumanb + CTplatinum-based CT1L squamous Risk of bias SuggestingNCT02775435
Keynote 042 (>=50%), 2018pembrolizumabplatinum-based CT1L, PDL1 positiveSuggestingNCT02220894
Keynote 042 (>=20%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive Risk of bias SuggestingNCT02220894

melanoma

KEYNOTE-001, 2014pembrolizumab 2mg/kgpembrolizumab 10mg/kg2L Exploratory NegativeNCT01295827
KEYNOTE 002 (2mg/kg Q3W), 2015pembrolizumab 2mg/kgchemotherapy2L Exploratory Suggesting NCT01704287
KEYNOTE 002 (10mg/kg Q3W), 2015pembrolizumab 10mg/kgchemotherapy2L Exploratory SuggestingNCT01704287
KEYNOTE-006 (every 2W), 2015pembrolizumab (every 2W)ipilimumab1L Risk of bias Suggesting NCT01866319
KEYNOTE-006 (every 3W), 2015pembrolizumab (every 3W)ipilimumab1L Risk of bias Suggesting NCT01866319
KEYNOTE-054, 2018pembrolizumabplaceboadjuvant Low risk of bias Conclusive NCT02362594

multiple myeloma

KEYNOTE-185, 2018pembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCT Risk of bias - NCT02579863
KEYNOTE-183, 2018pembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMM Risk of bias Negative NCT02576977

renal-cell carcinoma (advanced)

KEYNOTE-426 ongoing pembrolizumab + axitinibsunitinib - NCT02853331

urothelial carcinoma (advanced)

Keynote 361 monotherapypembrolizumabchemotherapyfirst line - NCT02853305
KEYNOTE-052, 2017pembrolizumab Exploratory - NCT02335424
KEYNOTE-045, 2017pembrolizumabchemotherapy2nd line Risk of bias SuggestingNCT02256436
Keynote 361 combination ongoing pembrolizumab + CTchemotherapyfirst line - NCT02853305



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons